Treatment of chronic renal failure with imidazole angiotensin-II

Details Treatment of chronic renal failure with imidazole angiotensin-II Treatment of chronic renal failure with imidazole angiotensin-II

1992-02-07

1993-05-11

Friedman, S. J.

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Phosphorus containing other than solely as part of an...

514256, 514279, 514359, 514381, 514385, A61K 3141, A61K 3144, A61K 3164, A61K 31415

Patent

active

052100790

ABSTRACT:
Substituted imidazoles such as 2-butyl-4-chloro-1-[(2'-(1H-tetrazol-5-yl)biphenyl-4-yl)methyl]-5-(hydroxy methyl)imidazole and 2-butyl-4-chloro-1-[(2'-carboxybiphenyl-4-yl)-methyl]-5-(hydroxymethyl)imi dazole and pharmaceutically acceptable salts thereof are useful for treating chronic renal failure, mediated by angiotensin-II.

REFERENCES:
patent: 3772315 (1973-11-01), Regel et al.
patent: 4207324 (1980-06-01), Matsumura et al.
patent: 4226878 (1980-10-01), Izuka
patent: 4301169 (1981-11-01), Yamanaka et al.
patent: 4328349 (1982-05-01), Grayboyes et al.
patent: 4340598 (1982-07-01), Furukawa et al.
patent: 4347364 (1982-08-01), Walser et al.
patent: 4347365 (1982-08-01), Walser et al.
patent: 4355040 (1982-11-01), Furukawa et al.
patent: 4379927 (1983-04-01), Vorbruggen et al.
patent: 4402966 (1983-09-01), Yamanaka et al.
patent: 4448781 (1984-05-01), Cross et al.
patent: 4463011 (1984-07-01), Ogata et al.
patent: 4533669 (1985-08-01), Yamanaka et al.
patent: 4602031 (1986-07-01), Yamanaka et al.
Pals, et al. 1971, Circ. Res. 29:673-681. "Role of the Pressor Action . . . ".
Zatz, et al. 1985, Proc. Nat. Acad. Sci. 82:5963-5967. "Predominance. . . ".
Anderson, et al. 1985, J. Clin. Invest. 76:612-619, "Control of . . . ".
Anderson & Brenner Hypertension: Pathophysiology, Diagnosis & Management Chapt. 72: pp. 1163-1176 (1990).
Wong, et al., Pharmacol. Exp. Ther., 215:104, 1980.
Dunn, Hospital Practice, 19:99, 1984.
Dzau, et al., N. Eng. J. Med., 310:347, 1984.
Lindgren, et al., Eur. J. Pharmacol., 135:383, 1987.
Zatz, et al., Kidney International, vol. 31, Suppl. 20, pp. S-123-129 (1987).
Schmidt et al., J. Cardiovascular Pharmacology, vol. 8, pp. S100-105 (1986).
Wong et al., Life Sciences, 27:1291-1297 (1980).
Anderson et al., Hypertension: Pathophysiology, Diagnosis, and Management, Chapter 73, pp. 1163-1176 (1990).
Anderson et al., Hypertension: Pathophysiology, Diagnosis, and Management, Chapter 104, pp. 1677-1687 (1990).
Torii, H., Takeda Kenkyushoho, 41, No. 3/4, 180-191, (1982).
Streeten et al., Handbook of Hypertension, vol. 5, pp. 246-247, (1984).
Keeton, T. K. et al., Pharmacol. Rev., vol. 31, pp. 81-227, (1981).
Weinberger, M. H. et al., Medical Clinics N. America, vol. 71, (1987).
Dunn, M. J., Hospital Practice, vol. 19, pp. 99-113 (1984).
Satoh et al., Circ. Res., 36/37 (Suppl. I):I-89 to 1-96 (1975).
Blasingham et al., Am. J. Physiol., vol. 2339, F360, (1980).
Wong et al., J. Pharmacol. Exp. Therm., vol. 219, pp. 104-109 (1980).
Raij et al., Journal of Hypertension Supplement, vol. 7, Suppl. 7, pp. S33-S37 (Sep. 1989).
Abdulkader et al., Brazilian Journal of Medical and Biological Research, 21 (2):233-239 (1988).
Magnusson et al., Kidney International Supplement 16, vol. 24, pp. S324-S326 (Dec. 1983).
Huland et al., Transplantation, 36(2):139-142 (Aug. 1983).
Mento et al., J. Cardiovascular Pharmacol., 8(4):670-675 (1986).
MacDonald et al., Kidney International, 31 (S20):S148-S153 (1987).
Anderson et al,, Am. J. Hypertens. 4(5): 11a-12A (1991).
Lafayette et al., Am. Soc. Nephrology, 23d. Ann. Mtg. (Dec. 2-5, 1990).
Hutchinson et al., Clinical Research, vol. 539, No. 2, p. 358A (1991).
H. Torii, Takeda Kenkyushoho, 40, No. 3/4, 180-191 (1982).
Streeten and Anderson, Handbook of Hypertension, vol. 5, Clinical Pharmacology of Antihypertensive Drugs, A. E. Doyle (Editor), Elsevier Science Publishers B. V., p. 246 (1984).
Satoh, et al., Cir. Res. 36/37 & Suppl. I):I-89, 1975.
Blasingham et al., Am. J. Physiol. 239:F360, 1980.
Wong et al., Abstract No. 30, Hypertension, p. 340. vol. 12, No. 3, Sep. 1988 High Blood Pressure Council Mtg., San Francisco, Calif., Sep. 28-Oct. 1, 1988, "X-6803 Methyl 2-N-Butyl-1-(4-(2-Carboxybenzamido) Benzyl-4-Chloroimidazole-5-Acetate, Sodium Salt): A Novel Nonpeptide Angiotension II Receptor Antagonist".
Chiu et al., Abstract No. 118.11, The Pharmacologist, vol. 30, p. A165, 1988, for ASPET mtg., Montreal, Canada, Oct. 9-13, 1988: "Nonpeptide Angiotensin II (AII) Receptor Antagonists: Structure Function Studies".
Wong et al., Nonpeptide Angiotensin II Receptor Antognists. I. Pharmacological Characterization of 2-n-Butyl-chloro-1-(2-chlorobenzyl)imidazole-5-acetic acid, sodium salt (S-8307), "J. Pharmacology and Experimental Therapeutics, "vol. 247, No. 1, pp. 1-7.

Affiliated with

Also associated with

Rating

Treatment of chronic renal failure with imidazole angiotensin-II does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Treatment of chronic renal failure with imidazole angiotensin-II, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Treatment of chronic renal failure with imidazole angiotensin-II will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-1350057